SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...

NS-136 is under development for the treatment of schizophrenia and psychosis in Alzheimer's disease. It is being developed based on NeuChime platform technology based on artificial intelligence. It is ...

CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

BGBC-354 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

Ulecaciclib is under clinical development by Aucentra Therapeutics and currently in Phase II for Cervical Cancer.

Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.